Earnings Call · Q4 FY2021·2022-03-28

Q4 21EPS -100.00%*·Rev n/aQ3 21EPS +33.33%·Rev n/aQ2 21EPS -17.71%·Rev n/aQ1 21EPS 0.00%·Rev n/a⚠ consensus missing

Acumen Pharmaceuticals, Inc. ABOS

Disclaimer*

John Woolford — Chief Financial Officer

Daniel O'Connell — Chief Executive Officer

Eric Siemers — Chief Medical Officer

Matt Zuga — Chief Financial Officer

−6.0%1d on move date−7.2% vs SPY3d−16.1%5d−12.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABOS calls or request research access.

More ABOS calls Browse calls Request research access